Nevertheless, our observation that iCAFs and myCAFs could be recovered albeit with some variation in three consecutively collected tumor biopsies, suggests that CD105 is a useful marker to enrich for those states by FACS, at least when it comes to luminal ER+ breast cancer. This evidence concerns the gene ESR1 and breast carcinoma.